BMC(301367.SZ)

Company Encyclopedia
View More
name
BMC
301367.SZ
BMC Medical Co., Ltd. researches, develops, manufactures, and supplies medical equipment and consumable in the field of respiratory health in China. It offers sleep-disordered breathing (SDB) diagnostic devices, non-invasive ventilators, high-flow nasal cannula oxygen therapy devices, oxygen concentrator, and respiratory consumables, such as various types of masks, breathing tubes, etc., as well as PAP devices and CPAP masks. The company also provides snoring, sleep apnea, asthma, and chronic obstructive pulmonary disease solutions.
872.18 B
301367.SZMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking15/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.28%B
    • Profit Margin20.03%A
    • Gross Margin56.30%B
  • Growth ScoreA
    • Revenue YoY34.70%A
    • Net Profit YoY38.35%B
    • Total Assets YoY8.61%B
    • Net Assets YoY6.60%B
  • Cash ScoreB
    • Cash Flow Margin499.17%C
    • OCF YoY34.70%A
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreA
    • Gearing Ratio15.08%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BMC released its performance for the first three quarters, with a net profit attributable to the parent company of 180 million yuan, an increase of 43.87%

    According to the Zhitong Finance APP, BMC released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 808 million yuan, a year-on-year increase of 34.24%. The net profit attributable to shareholders of the listed company was 180 million yuan, a year-on-year increase of 43.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 140 million yuan, a year-on-year increase of 63.41%. The basic earnings per share were 2.0252 yuan

    Zhitong·
    SZ
    301367
    +1.55%
    Zhitong·
    SZ
    301367
    +1.55%

    BMC released its performance for the first half of the year, with a net profit attributable to the parent company of 131 million yuan, an increase of 42.19%

    According to the Zhitong Finance APP, BMC released its semi-annual report for 2025, with operating revenue of 544 million yuan, a year-on-year increase of 42.30%. The net profit attributable to shareholders of the listed company was 131 million yuan, a year-on-year increase of 42.19%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 99.3161 million yuan, a year-on-year increase of 49.34%. The basic earnings per share were 1.48 yuan

    Zhitong·
    SZ
    301367
    +1.55%
    Zhitong·
    SZ
    301367
    +1.55%

    BMC multiple shareholders plan to reduce their holdings by no more than 3.5545 million shares

    According to the Zhitong Finance APP, BMC announced that the company's shareholder Nengjin Co., Ltd. and its concerted parties Guangzhou Jinyuan Venture Capital Partnership (Limited Partnership), Zhuhai Huanxuan Investment Center (Limited Partnership) and its concerted parties Shanghai Shengmin Venture Capital Partnership (Limited Partnership) and Nanjing Hehao Venture Capital Enterprise (Limited Partnership) plan to reduce their holdings in the company, with a total number not exceeding 3.5545 million shares

    Zhitong·
    SZ
    301367
    +1.55%
    Zhitong·
    SZ
    301367
    +1.55%

    BMC signed a strategic cooperation framework agreement around the sleep health ecosystem

    BMC has signed a strategic cooperation framework agreement with Hanyu Pharmaceutical and Hanyu Health, aiming to integrate the resources of the three parties in the field of sleep health and build a collaborative development ecosystem. The cooperation will focus on the prevention, treatment, and health management of sleep disorders, achieving mutual benefits through joint brand promotion

    Zhitong·
    SZ
    301367
    +1.55%
    Zhitong·
    SZ
    301367
    +1.55%

    BMC: Brain-computer interface technology is adaptable to the company's ventilators and other scenarios

    BMC stated on the Shenzhen Stock Exchange interactive platform that the company attaches great importance to the possibility of integrating brain-machine technology with existing products. The brain-machine interface technology is compatible with the company's ventilators and sleep devices in terms of application scenarios, making it a good direction for functional enhancement

    Zhitong·
    SZ
    301367
    +1.55%
    Zhitong·
    SZ
    301367
    +1.55%
    © 2025 Longbridge｜Disclaimer